THC and CBD Alone — A Single Defined Pharmacological Signal
An isolate strips the plant down to one active molecule.
- 1: Active compounds present (cannabinoid only, no terpenes)
- 3: Effect axes measured (sedation, mood, alertness)
- 40/100: Baseline sedation score (THC/CBD isolate reference point)
- Low: Reported variability (single-compound dosing is predictable)
Why isolates are the pharmacological control
One molecule, one dose-response curve, no confounds.
What isolate studies can and cannot show
Clean signal, but misses any whole-plant interactions.
Whole-Plant Extracts — Terpenes Enter the Picture
Full-spectrum extracts carry cannabinoids plus aromatic terpenes.
- 3: Terpenes modeled (myrcene, limonene, pinene)
- Sedating: Myrcene proposed effect (often paired with indica framing)
- Mood-elevating: Limonene proposed effect (citrus-scented, uplift claims)
- Alertness-promoting: Pinene proposed effect (pine-scented, clarity claims)
Terpenes as aromatic, not just olfactory, compounds
Terpenes are proposed to do more than smell.
Blend composition varies widely by cultivar
Terpene ratios differ strain to strain, batch to batch.
The Entourage Hypothesis — Modulated Binding and Added Effects
Terpenes may shift receptor binding or add their own effects.
- 2: Proposed mechanism types (receptor modulation, additive effect)
- ±35 pts: Entourage sedation shift (blend-dependent, proposed range)
- ±35 pts: Entourage mood shift (blend-dependent, proposed range)
- ±35 pts: Entourage alertness shift (blend-dependent, proposed range)
Receptor-modulation hypothesis
Terpenes proposed to alter cannabinoid receptor affinity slightly.
Additive-effect hypothesis
Terpenes may simply contribute their own independent effects.
What the Research Actually Supports — Preclinical vs Clinical
Most entourage claims come from preclinical or anecdotal sources.
- Very few: Rigorous human RCTs (entourage-specific clinical trials)
- More common: Preclinical/animal studies (cell and rodent models)
- Widespread: Anecdotal/marketing claims (consumer and industry framing)
- ~20-30%: Clinical evidence strength (cautious, preliminary rating)
Marketing framing vs rigorous assessment
The same claim looks very different under clinical scrutiny.
What would strengthen the evidence base
Controlled, blinded, dose-matched human trials are still needed.
A Plausible Hypothesis, Not Yet an Established Fact
Entourage effect stays a hypothesis pending stronger clinical proof.
- Plausible: Mechanism plausibility (biologically reasonable, unconfirmed magnitude)
- Not established: Clinical proof status (lacking rigorous human trials)
- Yes: Subjective differences reported (whole-plant vs isolate, self-reported)
- Cautious: Recommended stance (evidence-based skepticism advised)
Where the hypothesis stands today
Reasonable mechanism, unproven magnitude, evidence still developing.
Reading whole-plant product claims critically
Treat entourage marketing claims as hypotheses, not facts.